Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients

NCT03013556 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis

Interventions

DRUG: Group A, TDF
DRUG: Group B:TDF then TDF and Peginterferon alfa-2a
DRUG: Group C:TDF and Peginterferon alfa-2a then TDF

Sponsor

Ruijin Hospital